These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 19915350)

  • 21. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
    Gertz MA; Lacy MQ; Inwards DJ; Chen MG; Pineda AA; Gastineau DA; Greipp PR; Lust JA; Tefferi A; Witzig TE; Kyle RA; Litzow MR
    Bone Marrow Transplant; 1999 Feb; 23(3):221-6. PubMed ID: 10084252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
    Ahmad I; Islam T; Chanan-Khan A; Hahn T; Wentling D; Becker JL; McCarthy PL; Alam AR
    Bone Marrow Transplant; 2002 Apr; 29(7):577-80. PubMed ID: 11979306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma.
    Palumbo A; Avonto I; Bruno B; Falcone A; Scalzulli PR; Ambrosini MT; Bringhen S; Gay F; Rus C; Cavallo F; Falco P; Massaia M; Musto P; Boccadoro M
    Clin Lymphoma Myeloma; 2006 May; 6(6):475-7. PubMed ID: 16796778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced steady state-based peripheral blood stem cell harvest rate in multiple myeloma treated with bortezomib-based induction regimens.
    Manier S; Barthelemy M; Fouquet G; Prod'homme C; Le Ray E; Samarcq P; Noel MP; Terriou L; Facon T; Cossment C; Boulanger F; Leleu X
    Leukemia; 2012 Dec; 26(12):2552-4. PubMed ID: 22627696
    [No Abstract]   [Full Text] [Related]  

  • 25. High-dose treatment with autologous stem cell transplantation in multiple myeloma: past, present, and future.
    Björkstrand B; Gahrton G
    Semin Hematol; 2007 Oct; 44(4):227-33. PubMed ID: 17961721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.
    Harousseau JL; Attal M; Avet-Loiseau H; Marit G; Caillot D; Mohty M; Lenain P; Hulin C; Facon T; Casassus P; Michallet M; Maisonneuve H; Benboubker L; Maloisel F; Petillon MO; Webb I; Mathiot C; Moreau P
    J Clin Oncol; 2010 Oct; 28(30):4621-9. PubMed ID: 20823406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tandem transplants in the treatment of multiple myeloma. Pro.
    Fassas AB; Tricot G
    Clin Adv Hematol Oncol; 2004 May; 2(5):303-4. PubMed ID: 17682284
    [No Abstract]   [Full Text] [Related]  

  • 28. Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma.
    Leleu X; Fouquet G; Hebraud B; Roussel M; Caillot D; Chrétien ML; Arnulf B; Szalat R; Garderet L; Benajiba L; Pegourie B; Regny C; Royer B; Caulier A; Stoppa AM; Garciaz S; Touzeau C; Chaleteix C; Fermand JP; Loiseau HA; Facon T; Attal M; Moreau P;
    Leukemia; 2013 Nov; 27(11):2242-4. PubMed ID: 23558525
    [No Abstract]   [Full Text] [Related]  

  • 29. Hyperammonemia after high-dose chemotherapy and stem cell transplantation.
    Frere P; Canivet JL; Gennigens C; Rebeix JP; Fillet G; Beguin Y
    Bone Marrow Transplant; 2000 Aug; 26(3):343-5. PubMed ID: 10967577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is double autologous stem-cell transplantation appropriate for new multiple myeloma patients?
    van Rhee F
    Nat Clin Pract Oncol; 2008 Feb; 5(2):70-1. PubMed ID: 17984985
    [No Abstract]   [Full Text] [Related]  

  • 31. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.
    Lokhorst HM; Sonneveld P; Cornelissen JJ; Joosten P; van Marwijk Kooy M; Meinema J; Nieuwenhuis HK; van Oers MH; Richel DJ; Segeren CN; Veth G; Verdonck LF; Wijermans PW
    Bone Marrow Transplant; 1999 Feb; 23(4):317-22. PubMed ID: 10100574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current therapeutic strategy for multiple myeloma.
    Suzuki K
    Jpn J Clin Oncol; 2013 Feb; 43(2):116-24. PubMed ID: 23293370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
    Pitini V; Arrigo C; Aloi G; Micali C; La Gattuta G
    Bone Marrow Transplant; 2003 Jun; 31(11):1065; author reply 1067. PubMed ID: 12774062
    [No Abstract]   [Full Text] [Related]  

  • 34. Role of stem cell transplantation.
    Harousseau JL
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1157-74, x. PubMed ID: 17996593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toxicity of autologous hematopoietic cell transplantation in patients with multiple myeloma - comparison between two different induction regimens.
    Ram R; Magen-Nativ H; Vidal L; Herscovici C; Peck A; Raanani P; Shpilberg O; Yeshurun M
    Clin Transplant; 2012; 26(5):E549-54. PubMed ID: 23061765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination regimens using doxorubicin and pegylated liposomal doxorubicin prior to autologous transplantation in multiple myeloma.
    Moreau P
    Expert Rev Anticancer Ther; 2009 Jul; 9(7):885-90. PubMed ID: 19589027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thalidomide maintenance in multiple myeloma: certainties and controversies.
    Cavo M; Pantani L; Tacchetti P; Pallotti MC; Brioli A; Petrucci A; Zamagni E; Tosi P
    J Clin Oncol; 2009 Nov; 27(32):e186-7; author reply e188. PubMed ID: 19770366
    [No Abstract]   [Full Text] [Related]  

  • 38. Fourth biannual report of the Cochrane Haematological Malignancies Group.
    Kober T; Hülsewede H; Bohlius J; Engert A
    J Natl Cancer Inst; 2006 Apr; 98(8):E1. PubMed ID: 16622111
    [No Abstract]   [Full Text] [Related]  

  • 39. Bortezomib plus melphalan and prednisone for multiple myeloma.
    Avvisati G
    N Engl J Med; 2008 Dec; 359(24):2613; author reply 2613-4. PubMed ID: 19090032
    [No Abstract]   [Full Text] [Related]  

  • 40. Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma.
    Thompson PA; Prince HM; Seymour JF; Ritchie D; Stokes K; Burbury K; Wolf M; Peinert S; Joyce T; Harrison SJ
    Bone Marrow Transplant; 2011 May; 46(5):764-5. PubMed ID: 20676149
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.